EUVIMEDEUVIMED entdecken
Leitlinie

Systemic Therapy for Tumor Control in Metastatic Well-Differentiated Gastroenteropancreatic Neuroendocrine Tumors: ASCO Guideline

Jaydira Del Rivero iD, Kimberly Perez iD, Erin B Kennedy iD, Erik S Mittra, Namrata Vijayvergia iD, Junaid Arshad iD, Sandip Basu, Aman Chauhan iD, Arvind N Dasari iD, Andrew M Bellizzi iD, Alexandra Gangi iD, Erin Grady iD und 14 weitere

Journal of Clinical Oncology · 10.11.2023 · 41 (32) · 5049-5067

DOI: 10.1200/jco.23.01529 ↗

Kurz gefasst

Leitlinie in der Zeitschrift Journal of Clinical Oncology, erschienen am 10.11.2023. Verfasst von Jaydira Del Rivero und 25 weiteren Autor:innen. Beteiligte Einrichtung: Center for Cancer Research, National Cancer Institute, Bethesda, MD. Hauptthemen laut MEDLINE: Intestinal Neoplasms, Neuroendocrine Tumors, Pancreatic Neoplasms, Stomach Neoplasms. Die Arbeit wurde bisher 122-mal zitiert (Crossref) und nennt 83 Literaturangaben. Gefördert von: NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE To develop recommendations for systemic therapy for well-differentiated grade 1 (G1) to grade 3 (G3) metastatic gastroenteropancreatic neuroendocrine tumors (GEP-NETs). METHODS ASCO convened an Expert Panel to conduct a systematic review of relevant studies and develop recommendations for clinical practice. RESULTS Eight randomized controlled trials met the inclusion criteria for the systematic review. RECOMMENDATIONS Somatostatin analogs (SSAs) are recommended as first-line systemic therapy for most patients with G1-grade 2 (G2) metastatic well-differentiated GI-NETs. Observation is an option for patients with low-volume or slow-growing disease without symptoms. After progression on SSAs, peptide receptor radionuclide therapy (PRRT) is recommended as systematic therapy for patients with somatostatin receptor (SSTR)–positive tumors. Everolimus is an alternative second-line therapy, particularly in nonfunctioning NETs and patients with SSTR-negative tumors. SSAs are standard first-line therapy for SSTR-positive pancreatic (pan)NETs. Rarely, observation may be appropriate for asymptomatic patients until progression. Second-line systemic options for panNETs include PRRT (for SSTR-positive tumors), cytotoxic chemotherapy, everolimus, or sunitinib. For SSTR-negative tumors, first-line therapy options are chemotherapy, everolimus, or sunitinib. There are insufficient data to recommend particular sequencing of therapies. Patients with G1-G2 high-volume disease, relatively high Ki-67 index, and/or symptoms related to tumor growth may benefit from early cytotoxic chemotherapy. For G3 GEP-NETs, systemic options for G1-G2 may be considered, although cytotoxic chemotherapy is likely the most effective option for patients with tumor-related symptoms, and SSAs are relatively ineffective. Qualifying statements are provided to assist with treatment choice. Multidisciplinary team management is recommended, along with shared decision making with patients, incorporating their values and preferences, potential benefits and harms, and other characteristics and circumstances, such as comorbidities, performance status, geographic location, and access to care. Additional information is available at www.asco.org/gastrointestinal-cancer-guidelines .

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Intestinal NeoplasmsNeuroendocrine TumorsPancreatic NeoplasmsStomach NeoplasmsPractice Guidelines as TopicHumansEverolimusSomatostatinSunitinib

Substanzen

EverolimusSomatostatinSunitinib

Autor:innen und Institutionen

  • Center for Cancer Research, National Cancer Institute, Bethesda, MD.
  • Dana-Farber Cancer Institute, Boston, MA.
  • American Society of Clinical Oncology, Alexandria, VA.
  • Oregon Health & Science University, Portland, OR.
  • Fox Chase Cancer Center, Philadelphia, PA.
  • University of Arizona Cancer Center, Tucson, AZ.

ORCID-Profile: Jaydira Del Rivero, Kimberly Perez, Erin B Kennedy, Namrata Vijayvergia, Junaid Arshad, Aman Chauhan, Arvind N Dasari, Andrew M Bellizzi, Alexandra Gangi, Erin Grady, James R Howe, Nitya Raj, Heloisa P Soares, Michael C Soulen, Pamela L Kunz, Simron Singh, Thorvardur R Halfdanarson, Jonathan R Strosberg, Emily K Bergsland

Förderung

  • NCI NIH HHS

Zitieren

APA

Del Rivero, J., Perez, K., Kennedy, E. B., Mittra, E. S., Vijayvergia, N., Arshad, J., Basu, S., Chauhan, A., Dasari, A. N., Bellizzi, A. M., Gangi, A., Grady, E., Howe, J. R., Ivanidze, J., Lewis, M., Mailman, J., Raj, N., Soares, H. P., Soulen, M. C., …, & Bergsland, E. K. (2023). Systemic Therapy for Tumor Control in Metastatic Well-Differentiated Gastroenteropancreatic Neuroendocrine Tumors: ASCO Guideline. Journal of Clinical Oncology, 41(32), 5049-5067. https://doi.org/10.1200/jco.23.01529

Vancouver

Del Rivero J, Perez K, Kennedy EB, Mittra ES, Vijayvergia N, Arshad J, et al. Systemic Therapy for Tumor Control in Metastatic Well-Differentiated Gastroenteropancreatic Neuroendocrine Tumors: ASCO Guideline. Journal of Clinical Oncology. 2023;41(32):5049-5067. doi:10.1200/jco.23.01529

BibTeX
@article{DelRivero2023,
  author = {Del Rivero, Jaydira and Perez, Kimberly and Kennedy, Erin B and Mittra, Erik S and Vijayvergia, Namrata and Arshad, Junaid and Basu, Sandip and Chauhan, Aman and Dasari, Arvind N and Bellizzi, Andrew M and Gangi, Alexandra and Grady, Erin and Howe, James R and Ivanidze, Jana and Lewis, Mark and Mailman, Josh and Raj, Nitya and Soares, Heloisa P and Soulen, Michael C and White, Sarah B and Chan, Jennifer A and Kunz, Pamela L and Singh, Simron and Halfdanarson, Thorvardur R and Strosberg, Jonathan R and Bergsland, Emily K},
  title = {Systemic Therapy for Tumor Control in Metastatic Well-Differentiated Gastroenteropancreatic Neuroendocrine Tumors: ASCO Guideline},
  journal = {Journal of Clinical Oncology},
  year = {2023},
  volume = {41},
  number = {32},
  pages = {5049--5067},
  doi = {10.1200/jco.23.01529}
}
Kostenlos starten →